This is an observational study to assess the long-term safety of Entyvio (vedolizumab), or other similar biologic agents in patients with Ulcerative Colitis...
- Trial ID:
- Gauree G Konijeti, MD, MPH
- Be at least 18 years of age
- Be starting treatment with vedolizmnab (Entyvio) or any biologic agent for UC or CD
- Have received any prior treatment with vedolizumab (Entyvio)
- Be enrolled in another clinical trial that involves treatment for UC or CD
- Subjects will be asked to complete 2 questionnaires to evaluate their health status at every office visit and will continue to be routinely followed-up by their physician about every 6 months.